We caught up with Ernest Choy (Cardiff University, Cardiff, UK) to discuss olokizumab as a novel rheumatoid arthritis (RA) treatment option. The symposia ‘Taking the High Road: Olokizumab as a Novel Rheumatoid Arthritis (RA) Treatment Option’ was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
1.What is the rationale for the use of olokizumab in patients with rheumatoid arthritis?(0:12)
2.What clinical evidence supports the efficacy and safety of olokizumab in this indication?(0:38)
3.What are the advantages of olokizumab compared with other available IL-6 inhibitors?(1:28)
4.Which patients are most likely to benefit from olokizumab and in whom is it contraindicated?(1:56)
5.What will be the next steps in the clinical development of olokizumab in rheumatoid arthritis?(2:48)
Disclosures: Professor Choy has received speaker and consultancy fees from R-Pharm.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
